Zhejiang Huahai Pharmaceutical Co., Ltd. (SHA:600521)
China · Delayed Price · Currency is CNY 16.29
+0.29 (1.81%)
Apr 30, 2026, 3:00 PM CST
SHA:600521 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 8,587 | 9,495 | 8,249 | 8,183 | 6,603 |
Other Revenue | - | 52.87 | 59.54 | 82.56 | 40.95 |
| 8,587 | 9,547 | 8,309 | 8,266 | 6,644 | |
Revenue Growth (YoY) | -10.06% | 14.91% | 0.52% | 24.42% | 2.44% |
Cost of Revenue | 3,422 | 3,738 | 3,376 | 3,180 | 2,671 |
Gross Profit | 5,166 | 5,809 | 4,933 | 5,086 | 3,973 |
Selling, General & Admin | 3,136 | 3,143 | 2,592 | 2,534 | 2,448 |
Research & Development | 1,229 | 986.69 | 982.99 | 925.53 | 942.26 |
Other Operating Expenses | -32.98 | 18.41 | 5.69 | 3.63 | 65.21 |
Operating Expenses | 4,332 | 4,185 | 3,572 | 3,508 | 3,470 |
Operating Income | 833.51 | 1,625 | 1,360 | 1,578 | 502.48 |
Interest Expense | - | -219.8 | -231.69 | -220.02 | -166.34 |
Interest & Investment Income | 18.8 | 53.22 | 39.48 | 25.83 | 180.61 |
Currency Exchange Gain (Loss) | - | 76.9 | 60.1 | 208.94 | -50.99 |
Other Non Operating Income (Expenses) | -251.71 | -5.8 | -5.14 | -3.91 | -4.32 |
EBT Excluding Unusual Items | 600.6 | 1,529 | 1,223 | 1,589 | 461.44 |
Impairment of Goodwill | - | - | -6.46 | - | - |
Gain (Loss) on Sale of Investments | 48.74 | -98.21 | -162.9 | -70 | 299.81 |
Gain (Loss) on Sale of Assets | 0 | 2.33 | -0.29 | -16.1 | -9.59 |
Asset Writedown | -205.46 | -30.13 | -32.95 | -2 | -0.16 |
Other Unusual Items | - | 60.55 | 79.92 | 8.23 | 35.42 |
Pretax Income | 443.88 | 1,464 | 1,100 | 1,509 | 786.93 |
Income Tax Expense | 216.55 | 356.15 | 283.07 | 332.89 | 306.28 |
Earnings From Continuing Operations | 227.33 | 1,107 | 817.25 | 1,176 | 480.64 |
Minority Interest in Earnings | 39.07 | 11.52 | 13.22 | -8.25 | 6.89 |
Net Income | 266.4 | 1,119 | 830.47 | 1,168 | 487.54 |
Net Income to Common | 266.4 | 1,119 | 830.47 | 1,168 | 487.54 |
Net Income Growth | -76.19% | 34.74% | -28.88% | 139.52% | -47.57% |
Shares Outstanding (Basic) | 1,480 | 1,449 | 1,457 | 1,442 | 1,434 |
Shares Outstanding (Diluted) | 1,480 | 1,449 | 1,457 | 1,460 | 1,434 |
Shares Change (YoY) | 2.12% | -0.52% | -0.19% | 1.80% | -1.30% |
EPS (Basic) | 0.18 | 0.77 | 0.57 | 0.81 | 0.34 |
EPS (Diluted) | 0.18 | 0.77 | 0.57 | 0.80 | 0.34 |
EPS Growth | -76.62% | 35.09% | -28.75% | 135.29% | -46.88% |
Free Cash Flow | -735.96 | 319.33 | 624.63 | -1,074 | -1,496 |
Free Cash Flow Per Share | -0.50 | 0.22 | 0.43 | -0.73 | -1.04 |
Dividend Per Share | - | 0.250 | 0.200 | 0.240 | 0.100 |
Dividend Growth | - | 25.00% | -16.67% | 140.00% | -50.00% |
Gross Margin | 60.16% | 60.85% | 59.37% | 61.53% | 59.80% |
Operating Margin | 9.71% | 17.02% | 16.37% | 19.09% | 7.56% |
Profit Margin | 3.10% | 11.72% | 9.99% | 14.13% | 7.34% |
Free Cash Flow Margin | -8.57% | 3.35% | 7.52% | -12.99% | -22.52% |
EBITDA | 1,845 | 2,510 | 2,141 | 2,230 | 1,050 |
EBITDA Margin | 21.49% | 26.29% | 25.76% | 26.98% | 15.81% |
D&A For EBITDA | 1,011 | 885.71 | 780.37 | 652.55 | 547.8 |
EBIT | 833.51 | 1,625 | 1,360 | 1,578 | 502.48 |
EBIT Margin | 9.71% | 17.02% | 16.37% | 19.09% | 7.56% |
Effective Tax Rate | 48.79% | 24.33% | 25.73% | 22.06% | 38.92% |
Revenue as Reported | - | 9,547 | 8,309 | 8,266 | 6,644 |
Advertising Expenses | - | 1,417 | 1,036 | 1,034 | 999.39 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.